Skip to Content

Promising Efficacy with FLOT-CROSS in Patients with Oligometastatic Esophageal Adenocarcinoma

A recent study evaluates the feasibility and safety of combining FLOT chemotherapy and CROSS chemoradiotherapy (TNT FLOT-CROSS) in the treatment of adenocarcinoma of the esophagus and junction in patients with oligometastases. Charlène J. van der Zijden elaborates on the study on this year’s ASCO GI congress in this MEDtalk.

Charlène J. van der Zijden

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top